Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

46461

Supelco

Metronidazole

VETRANAL®, analytical standard

Sinónimos:

2-Methyl-5-nitroimidazole-1-ethanol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C6H9N3O3
Número de CAS:
443-48-1
Peso molecular:
171.15
Beilstein:
611683
Número CE:
207-136-1
Número MDL:
MFCD00009750
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329757194
NACRES:
NA.24

grado

analytical standard

Nivel de calidad

200

Línea del producto

VETRANAL®

caducidad

limited shelf life, expiry date on the label

técnicas

HPLC: suitable
gas chromatography (GC): suitable

mp

159-161 °C (lit.)

espectro de actividad antibiótica

Gram-negative bacteria
parasites

aplicaciones

clinical testing

formato

neat

Modo de acción

DNA synthesis | interferes

temp. de almacenamiento

2-8°C

cadena SMILES

CC1=NC=C([N+]([O-])=O)N1CCO

InChI

1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

Clave InChI

VAOCPAMSLUNLGC-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Chemical structure: imidazole

Aplicación

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Productos recomendados

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Información legal

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H340,H350,H373

Clasificaciones de peligro

Carc. 1B - Muta. 1B - STOT RE 2

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Equipo de protección personal

dust mask type N95 (US), Eyeshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
BCCJ4839
BCCG8315
BCCB0355
BCBX3839
BCBW4436

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 7

1 of 7

Ronidazole-d3 VETRANAL®, analytical standard

Supelco

34217

Ronidazole-d3

Ronidazole analytical standard

Supelco

R7635

Ronidazole

Mebendazole analytical standard, ≥98% (HPLC)

Supelco

M2523

Mebendazole

Metronidazole impurity A European Pharmacopoeia (EP) Reference Standard

Y0000087

Metronidazole impurity A

Trimetoprim VETRANAL®, analytical standard

Supelco

46984

Trimetoprim

vibrant-m

M1851000

Metronidazole benzoate

Dicloxacillin sodium salt hydrate VETRANAL®, analytical standard

Supelco

46182

Dicloxacillin sodium salt hydrate

Sonja Löfmark et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 1, S16-S23 (2010-01-14)
Metronidazole has been used for the treatment of infections for >45 years and is still successfully used for the treatment of trichomoniasis, amoebiasis, and giardiasis. Anaerobic bacterial infections caused by Bacteroides species, fusobacteria, and clostridia respond favorably to metronidazole therapy.
Konstantinos Z Vardakas et al.
International journal of antimicrobial agents, 40(1), 1-8 (2012-03-09)
The objective of this review was to evaluate the frequency of treatment failure and recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or metronidazole in recently performed studies (last 10 years). Searches in PubMed and Scopus were performed
T H I Brummer et al.
BJOG : an international journal of obstetrics and gynaecology, 120(10), 1269-1276 (2013-06-22)
To evaluate cefuroxime and metronidazole antibiotic prophylaxis. Observational nonrandomised 1-year prospective cohort study. Fifty-three hospitals in Finland. A total of 5279 women undergoing hysterectomy for benign indications, with cefuroxime given to 4301 and metronidazole given to 2855. Excluding other antibiotics
Christina M Surawicz et al.
The American journal of gastroenterology, 108(4), 478-498 (2013-02-27)
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks
Amber Howerton et al.
The Journal of infectious diseases, 207(10), 1498-1504 (2013-02-20)
Clostridium difficile infection (CDI) is a leading cause of antibiotic-associated diarrhea. The infective form of C. difficile is the spore, but the vegetative bacterium causes the disease. Because C. difficile spore germination is required for symptomatic infection, antigermination approaches could
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico